2-苯基环丙基氨基甲酸叔丁酯 | 92644-77-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-苯基环丙基氨基甲酸叔丁酯
• 中文别名: (2-苯基环丙基)氨基甲酸叔丁酯
• 英文名称: tert-butyl (2-phenylcyclopropyl)carbamate
• 英文别名: N-Boc-2-phenylcyclopropylamine；tert-butyl N-(2-phenylcyclopropyl)carbamate
• CAS: 92644-77-4
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: MBZAGPLGLMIZOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-苯基环丙基氨基甲酸叔丁酯 在 盐酸 、 4-二甲氨基吡啶 、 iron(III) chloride 、 二叔丁基过氧化物 、 水 、 potassium carbonate 、 sodium iodide 作用下， 以 1,4-二氧六环 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 60.0h， 生成 肉桂醛
  参考文献：
  名称：

  Iron-Catalyzed Oxidative C(3)–H Functionalization of Amines

  摘要：

  Fe-catalyzed direct dehydrogenative C(3)-functionalization of tertiary arylamines was developed via activation of the sp(3) C(3)-H bond. The reaction is applicable to both cyclic and acyclic amines. The key process is the catalytic desaturative enamine formation from tertiary amines and position-selective C-C bond formation (addition to nitro olefins) at the beta-carbon. Products can be converted to versatile and unique nitrogen-containing molecules.

  DOI：

  10.1021/ol400568u
• 作为产物：
  描述：

  2-苯基环丙烷羧酸乙酯 在 甲醇 、 叠氮磷酸二苯酯 、 三乙胺 、 potassium hydroxide 作用下， 以 环己烷 为溶剂， 反应 21.0h， 生成 2-苯基环丙基氨基甲酸叔丁酯
  参考文献：
  名称：

  [EN] KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
  [FR] INHIBITEURS DE KDM1A POUR LE TRAITEMENT D'UNE MALADIE

  摘要：

  本文披露了新化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制KDMIA的方法，以及增加人类或动物主体中γ球蛋白基因表达的方法，用于治疗镰状细胞病等疾病。

  公开号：

  WO2014164867A1

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• The first synthesis of nitro-substituted cyclopropanes and spiropentanes via oxidation of the corresponding amino derivatives
  作者：Yuliya A. Volkova、Olga A. Ivanova、Ekaterina M. Budynina、Eugene V. Revunov、Elena B. Averina

  DOI：10.1016/j.tetlet.2009.03.165

  日期：2009.6

  A novel approach to nitro-substituted cyclopropanes and spiropentanes via oxidation of the corresponding amines with dimethyldioxirane is reported. The method is used successfully for the preparation of a series of nitrocyclopropanes as well as for the first synthesis of 1,4-dinitrospiro[2.2]pentane.

  据报道，通过相应的胺与二甲基二环氧乙烷的氧化反应，制得硝基取代的环丙烷和螺环戊烷的新方法。该方法已成功用于一系列硝基环丙烷的制备以及1,4-二硝基螺[2.2]戊烷的首次合成。
• CYCLOPROPANAMINE COMPOUND AND USE THEREOF
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150266881A1

  公开（公告）日：2015-09-24

  The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R 1 , R 2 and R 3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R 1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R 2 and R 3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

  本发明提供一种具有赖氨酸特异性去甲基化酶1抑制作用的化合物，可用作预防或治疗精神分裂症、阿尔茨海默病、帕金森病或亨廷顿病等疾病的药物。本发明涉及一种由下式表示的化合物： 其中A是一个烃基，可选地具有取代基，或者是一个杂环基，可选地具有取代基；B是一个苯环，可选地具有进一步的取代基；R1、R2和R3分别是氢原子，或者是一个烃基，可选地具有取代基，或者是一个杂环基，可选地具有取代基；A和R1可选地结合在一起，与相邻的氮原子一起形成一个可选地具有取代基的环基；而R2和R3可选地结合在一起，与相邻的氮原子一起形成一个可选地具有取代基的环基，或其盐。
• Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
  申请人：Benedict Suzanne

  公开号：US20060004052A1

  公开（公告）日：2006-01-05

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R 2 , R 3 and R 4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

  蛋白激酶（例如CHK-1）抑制下列式子中三环化合物（其中R2，R3和R4如规范中定义）的药物组合物（或其盐）在单独使用或与具有抗肿瘤作用的抗肿瘤剂或治疗性放射线组合使用时，可用于治疗癌症等疾病或病况。
• TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY
  申请人：Benedict Suzanne

  公开号：US20070135415A1

  公开（公告）日：2007-06-14

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R 2 , R 3 and R 4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.

  蛋白激酶，例如CHK-1，抑制以下式子中三环化合物（其中R2，R3和R4如规范所定义）的制剂（或其盐）的有效量的制药组合物，可用作单一剂量或与抗肿瘤剂或具有抗肿瘤作用的治疗性放射线组合使用，用于治疗癌症等疾病或病情。本发明涉及制备和使用这种化合物。